Fact Check: "Only one out of nine patients in a trial saw tumor shrinkage from ivermectin."
What We Know
The claim that "only one out of nine patients in a trial saw tumor shrinkage from ivermectin" lacks direct corroboration from available studies. Ivermectin, traditionally known as an antiparasitic drug, has recently been investigated for its potential anticancer properties. Research indicates that ivermectin can inhibit tumor proliferation and metastasis in various cancer types, and it has been shown to have antitumor effects in vitro and in vivo (source-1, source-2). However, specific clinical trial results detailing the exact number of patients experiencing tumor shrinkage are not readily available in the literature.
Analysis
The claim appears to be a misrepresentation or oversimplification of the findings from ongoing research into ivermectin's anticancer effects. While some studies have reported positive outcomes regarding tumor shrinkage and cancer cell inhibition, such as the ability of ivermectin to significantly inhibit cancer cell motility and metastasis (source-3), there is no definitive trial data that supports the specific statistic of "one out of nine patients."
Moreover, a phase II clinical trial is currently examining the effects of ivermectin in combination with pembrolizumab for metastatic triple-negative breast cancer (source-4). However, results from this trial have not yet been published, making it difficult to assess the accuracy of the claim based on current evidence.
The sources discussing ivermectin's potential in cancer treatment are generally credible, being published in peer-reviewed journals. However, they do not provide specific data on patient outcomes in the context of the claim. Therefore, while ivermectin shows promise as a cancer treatment, the claim about the specific statistic of tumor shrinkage lacks sufficient evidence and context.
Conclusion
Needs Research. The claim that "only one out of nine patients in a trial saw tumor shrinkage from ivermectin" is not substantiated by the current body of research. While ivermectin is being investigated for its anticancer properties, specific trial results that would confirm or deny this statistic are not available. Further research and published clinical trial results are necessary to provide clarity on this matter.
